vs
Core Natural Resources, Inc.（CNR）とRevvity（RVTY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Core Natural Resources, Inc.の直近四半期売上が大きい（$1.0B vs $772.1M、Revvityの約1.4倍）。Revvityの純利益率が高く（12.7% vs -7.6%、差は20.3%）。Core Natural Resources, Inc.の前年同期比売上増加率が高い（81.8% vs 5.9%）。Revvityの直近四半期フリーキャッシュフローが多い（$161.8M vs $26.0M）。過去8四半期でCore Natural Resources, Inc.の売上複合成長率が高い（38.1% vs 9.0%）
Arch Resources（旧社名Arch Coal）は米国の石炭採掘・加工企業で、ピーボディエナジーに次ぐ米国第2位の石炭供給業者です。2011年時点の国内シェアは15%で、主に低硫黄の瀝青炭・亜瀝青炭を採掘・加工・販売し、主な需要先は発電事業者です。
レブィティ（Revvity, Inc.）は米国のライフサイエンス・診断事業を手がける企業で、製薬およびバイオテクノロジー業界を主な顧客とし、特に新たな細胞治療や遺伝子治療の開発に関連するサービス・製品を提供している。前身は多岐にわたる事業を展開してきた老舗企業パーキンエルマーである。
CNR vs RVTY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.0B | $772.1M |
| 純利益 | $-79.0M | $98.4M |
| 粗利率 | — | — |
| 営業利益率 | -9.3% | 14.5% |
| 純利益率 | -7.6% | 12.7% |
| 売上前年比 | 81.8% | 5.9% |
| 純利益前年比 | -356.3% | 3.9% |
| EPS（希薄化後） | $-1.51 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $573.6M | $729.4M | ||
| Q3 24 | $553.4M | $684.0M | ||
| Q2 24 | $490.7M | $691.7M | ||
| Q1 24 | $546.7M | $649.9M |
| Q4 25 | $-79.0M | $98.4M | ||
| Q3 25 | $31.6M | $46.7M | ||
| Q2 25 | $-36.6M | $53.9M | ||
| Q1 25 | $-69.3M | $42.2M | ||
| Q4 24 | $30.8M | $94.6M | ||
| Q3 24 | $95.6M | $94.4M | ||
| Q2 24 | $58.1M | $55.4M | ||
| Q1 24 | $101.9M | $26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
| Q4 25 | -9.3% | 14.5% | ||
| Q3 25 | -1.2% | 11.7% | ||
| Q2 25 | -1.7% | 12.6% | ||
| Q1 25 | -5.3% | 10.9% | ||
| Q4 24 | 6.6% | 16.3% | ||
| Q3 24 | 21.2% | 14.3% | ||
| Q2 24 | 14.6% | 12.4% | ||
| Q1 24 | 22.7% | 6.8% |
| Q4 25 | -7.6% | 12.7% | ||
| Q3 25 | 3.2% | 6.7% | ||
| Q2 25 | -3.3% | 7.5% | ||
| Q1 25 | -6.8% | 6.4% | ||
| Q4 24 | 5.4% | 13.0% | ||
| Q3 24 | 17.3% | 13.8% | ||
| Q2 24 | 11.8% | 8.0% | ||
| Q1 24 | 18.6% | 4.0% |
| Q4 25 | $-1.51 | $0.86 | ||
| Q3 25 | $0.61 | $0.40 | ||
| Q2 25 | $-0.70 | $0.46 | ||
| Q1 25 | $-1.38 | $0.35 | ||
| Q4 24 | $1.04 | $0.77 | ||
| Q3 24 | $3.22 | $0.77 | ||
| Q2 24 | $1.96 | $0.45 | ||
| Q1 24 | $3.39 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $432.2M | $919.9M |
| 総負債低いほど良い | $354.2M | — |
| 株主資本純資産 | $3.7B | $7.3B |
| 総資産 | $6.1B | $12.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.10× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $432.2M | $919.9M | ||
| Q3 25 | $444.7M | $931.4M | ||
| Q2 25 | $413.2M | $991.8M | ||
| Q1 25 | $388.5M | $1.1B | ||
| Q4 24 | $460.2M | $1.2B | ||
| Q3 24 | $331.7M | $1.2B | ||
| Q2 24 | $216.1M | $2.0B | ||
| Q1 24 | $172.6M | $1.7B |
| Q4 25 | $354.2M | — | ||
| Q3 25 | $334.5M | — | ||
| Q2 25 | $334.0M | — | ||
| Q1 25 | $329.8M | — | ||
| Q4 24 | $94.8M | — | ||
| Q3 24 | $83.7M | — | ||
| Q2 24 | $184.9M | — | ||
| Q1 24 | $185.5M | — |
| Q4 25 | $3.7B | $7.3B | ||
| Q3 25 | $3.8B | $7.4B | ||
| Q2 25 | $3.8B | $7.6B | ||
| Q1 25 | $3.9B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.5B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B | ||
| Q1 24 | $1.4B | $7.8B |
| Q4 25 | $6.1B | $12.2B | ||
| Q3 25 | $6.2B | $12.1B | ||
| Q2 25 | $6.2B | $12.4B | ||
| Q1 25 | $6.3B | $12.4B | ||
| Q4 24 | $2.9B | $12.4B | ||
| Q3 24 | $2.8B | $12.8B | ||
| Q2 24 | $2.7B | $13.4B | ||
| Q1 24 | $2.7B | $13.4B |
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.09× | — | ||
| Q2 25 | 0.09× | — | ||
| Q1 25 | 0.08× | — | ||
| Q4 24 | 0.06× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.13× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $107.3M | $182.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $26.0M | $161.8M |
| FCFマージンFCF / 売上 | 2.5% | 21.0% |
| 設備投資強度設備投資 / 売上 | 7.8% | 2.6% |
| キャッシュ転換率営業CF / 純利益 | — | 1.85× |
| 直近12ヶ月FCF直近4四半期 | $21.2M | $509.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $107.3M | $182.0M | ||
| Q3 25 | $87.9M | $138.5M | ||
| Q2 25 | $220.2M | $134.3M | ||
| Q1 25 | $-109.6M | $128.2M | ||
| Q4 24 | $121.3M | $174.2M | ||
| Q3 24 | $161.3M | $147.9M | ||
| Q2 24 | $116.3M | $158.6M | ||
| Q1 24 | $77.5M | $147.6M |
| Q4 25 | $26.0M | $161.8M | ||
| Q3 25 | $38.6M | $120.0M | ||
| Q2 25 | $131.0M | $115.5M | ||
| Q1 25 | $-174.5M | $112.2M | ||
| Q4 24 | $80.5M | $149.8M | ||
| Q3 24 | $121.9M | $125.6M | ||
| Q2 24 | $60.9M | $136.6M | ||
| Q1 24 | $35.1M | $129.7M |
| Q4 25 | 2.5% | 21.0% | ||
| Q3 25 | 3.9% | 17.2% | ||
| Q2 25 | 11.9% | 16.0% | ||
| Q1 25 | -17.1% | 16.9% | ||
| Q4 24 | 14.0% | 20.5% | ||
| Q3 24 | 22.0% | 18.4% | ||
| Q2 24 | 12.4% | 19.7% | ||
| Q1 24 | 6.4% | 20.0% |
| Q4 25 | 7.8% | 2.6% | ||
| Q3 25 | 4.9% | 2.6% | ||
| Q2 25 | 8.1% | 2.6% | ||
| Q1 25 | 6.4% | 2.4% | ||
| Q4 24 | 7.1% | 3.4% | ||
| Q3 24 | 7.1% | 3.3% | ||
| Q2 24 | 11.3% | 3.2% | ||
| Q1 24 | 7.7% | 2.7% |
| Q4 25 | — | 1.85× | ||
| Q3 25 | 2.78× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 3.94× | 1.84× | ||
| Q3 24 | 1.69× | 1.57× | ||
| Q2 24 | 2.00× | 2.87× | ||
| Q1 24 | 0.76× | 5.67× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CNR
| Other | $397.4M | 38% |
| Power Generation | $376.5M | 36% |
| PRB | $183.0M | 18% |
| Metallurgical | $42.0M | 4% |
| Industrial | $34.1M | 3% |
| Terminal Revenue | $6.4M | 1% |
| Other Revenue | $3.0M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
